KR102477187B1 - 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 - Google Patents

피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 Download PDF

Info

Publication number
KR102477187B1
KR102477187B1 KR1020207023803A KR20207023803A KR102477187B1 KR 102477187 B1 KR102477187 B1 KR 102477187B1 KR 1020207023803 A KR1020207023803 A KR 1020207023803A KR 20207023803 A KR20207023803 A KR 20207023803A KR 102477187 B1 KR102477187 B1 KR 102477187B1
Authority
KR
South Korea
Prior art keywords
group
ring
pharmaceutically acceptable
hydrocarbyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207023803A
Other languages
English (en)
Korean (ko)
Other versions
KR20200118062A (ko
Inventor
리 첸
큉 샤오
샤오지안 수
샤오웬 리
Original Assignee
장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810044308.4A external-priority patent/CN110041327B/zh
Priority claimed from CN201811517425.4A external-priority patent/CN111303147B/zh
Application filed by 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 filed Critical 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드
Publication of KR20200118062A publication Critical patent/KR20200118062A/ko
Application granted granted Critical
Publication of KR102477187B1 publication Critical patent/KR102477187B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
KR1020207023803A 2018-01-17 2019-01-16 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 Active KR102477187B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810044308.4 2018-01-17
CN201810044308.4A CN110041327B (zh) 2018-01-17 2018-01-17 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201811517425.4A CN111303147B (zh) 2018-12-12 2018-12-12 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201811517425.4 2018-12-12
PCT/CN2019/071902 WO2019141179A1 (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用

Publications (2)

Publication Number Publication Date
KR20200118062A KR20200118062A (ko) 2020-10-14
KR102477187B1 true KR102477187B1 (ko) 2022-12-12

Family

ID=67301986

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023803A Active KR102477187B1 (ko) 2018-01-17 2019-01-16 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용

Country Status (11)

Country Link
US (1) US11247993B2 (enExample)
EP (1) EP3753936B1 (enExample)
JP (1) JP7352297B2 (enExample)
KR (1) KR102477187B1 (enExample)
CN (4) CN111848615B (enExample)
AU (1) AU2019210414B2 (enExample)
CA (1) CA3088926A1 (enExample)
PH (1) PH12020551264A1 (enExample)
SG (1) SG11202011447UA (enExample)
WO (1) WO2019141179A1 (enExample)
ZA (1) ZA202007143B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN111386276B (zh) 2017-10-06 2023-06-23 盐野义制药株式会社 制备取代的多环吡啶酮衍生物的立体选择性方法
CN118878544A (zh) * 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
CN112118891B (zh) * 2019-04-01 2023-10-31 尼坎医疗公司 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
CN111909174B (zh) * 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN112574170A (zh) * 2019-09-29 2021-03-30 江西东邦药业有限公司 一种二苯并七元环衍生物及其制备方法和应用
WO2021129602A1 (zh) * 2019-12-23 2021-07-01 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
CN113583022B (zh) * 2020-08-11 2025-03-18 石家庄迪斯凯威医药科技有限公司 多环化合物及其药物组合物和用途
CN115385932A (zh) * 2021-05-22 2022-11-25 江西彩石医药科技有限公司 吡啶酮衍生物的中间体及其制备方法
KR20250078466A (ko) * 2022-10-08 2025-06-02 스자좡 디스커버리 메디슨 테크놀로지 컴퍼니 리미티드 인플루엔자 바이러스 억제 유도체 및 그 용도
CN117003771B (zh) * 2022-11-09 2024-02-02 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
CN116789556A (zh) * 2023-05-26 2023-09-22 康化（上海）新药研发有限公司 一种含环丙氧基乙胺的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2017104691A1 (ja) 2015-12-15 2017-06-22 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
JP2017137291A (ja) * 2016-02-03 2017-08-10 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927710B2 (en) 2009-06-15 2015-01-06 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
MX377396B (es) * 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
SG11201708721XA (en) 2015-04-28 2017-11-29 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof
KR20190018469A (ko) * 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2017104691A1 (ja) 2015-12-15 2017-06-22 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
JP2017137291A (ja) * 2016-02-03 2017-08-10 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ

Also Published As

Publication number Publication date
AU2019210414A1 (en) 2020-09-03
US11247993B2 (en) 2022-02-15
CN111848615A (zh) 2020-10-30
KR20200118062A (ko) 2020-10-14
AU2019210414B2 (en) 2021-04-01
CN110637016B (zh) 2020-08-18
CN111848614A (zh) 2020-10-30
CN111848614B (zh) 2021-11-23
CN111848616B (zh) 2021-11-23
EP3753936A1 (en) 2020-12-23
EP3753936A4 (en) 2022-03-23
US20190367517A1 (en) 2019-12-05
JP7352297B2 (ja) 2023-09-28
CN111848616A (zh) 2020-10-30
PH12020551264A1 (en) 2021-05-31
CA3088926A1 (en) 2019-07-25
CN111848615B (zh) 2022-05-17
CN110637016A (zh) 2019-12-31
ZA202007143B (en) 2022-04-28
EP3753936B1 (en) 2026-04-08
JP2021511374A (ja) 2021-05-06
WO2019141179A1 (zh) 2019-07-25
SG11202011447UA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
KR102477187B1 (ko) 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용
AU2020275818B2 (en) Fluorine-containing compound and anti-cancer medical use thereof
JP7671503B2 (ja) Ｎ－メチル－２－ピリドンを含む化合物、および薬学的に許容される塩
CN110041327B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
EP1256576B1 (en) Fused imidazolium derivatives
JP2019069940A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
KR20210005629A (ko) 인자 XIIa 억제제
WO2008024337A2 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TW202135831A (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
AU2016382372B2 (en) Sulfonamide derivative and preparation method and use thereof
CZ2003467A3 (cs) Fenoxybenzylaminové deriváty jako selektivní inhibitory reuptake serotoninu
CN105073114A (zh) 用于呼吸疾病的药物
TW202502346A (zh) 作為at2r拮抗劑的雜環化合物及其用途
KR20250038236A (ko) 코로나바이러스 감염 치료용 화합물
CN117247380A (zh) 一种噻唑类衍生物及其药物组合物与应用
WO2022222911A1 (zh) 嘧啶酮化合物及其用途
HK40032909A (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
EA045400B1 (ru) Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства
CN115677703A (zh) 吡啶酮类化合物及其用途
RU2656603C1 (ru) Замещенные 2-метилиден-5-(фениламино)-2,3-дигидротиофен-3-оны для лечения лейкозов с транслокациями mll-гена и других онкологических заболеваний
JP2017525733A (ja) Ｆｔｌ３およびｊａｋの阻害剤としての大環状ｎ−アリール−トリシクロピリミジン−２−アミンポリエーテルの誘導体
HK40087540A (zh) 免疫调节剂及其组合物和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200818

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200911

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220426

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration